Effect of administration of lovastatin on the development of late pulmonary effects after whole-lung irradiation in a murine model

Radiation Research

Volumn 161, Issue 5, 2004, Pages 560-567

  Williams, Jacqueline P ^a   Hernady, Eric ^a   Johnston, Carl J ^a   Reed, Christina M ^a   Fenton, Bruce ^a   Okunieff, Paul ^a   Finkelstein, Jacob N ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; COLLAGEN; MESSENGER RNA; MEVINOLIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN; STATINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CELL INTERACTION; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; INFLAMMATORY CELL; IRRADIATION; LUNG CANCER; LYMPHOCYTE SUBPOPULATION; MONONUCLEAR CELL; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; RADIATION RESPONSE; RNA ANALYSIS; ANIMAL; BREATHING; C57BL MOUSE; COMPARATIVE STUDY; DOSE RESPONSE; EVALUATION; FEMALE; LUNG; METABOLISM; PATHOLOGY; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INJURY; SURVIVAL RATE;

ANIMALIA; MURINAE;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; LOVASTATIN; LUNG; MICE; MICE, INBRED C57BL; RADIATION DOSAGE; RADIATION INJURIES; RESPIRATION; SURVIVAL RATE;

EID: 3042763035     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR3168     Document Type: Article

References (56)

1. P. Rubin, D. L. Shapiro, J. N. Finkelstein and D. P. Penney, The early release of surfactant following lung irradiation of alveolar type II cells. Int. J. Radiat. Oncol. Biol. Phys. 6, 75-77 (1980).
2. D. P. Penney, D. W. Siemann, P. Rubin, D. L. Shapiro, J. Finkelstein and R. A. Cooper, Jr., Morphologic changes reflecting early and late effects of irradiation of the distal lung of the mouse: a review. Scan. Electron Microsc. 41, 3-425 (1982).
3. D. P. Penney, P. Van Houtte, D. W. Siemann, W. A. Rosenkrans, Jr., P. Rubin and R. A. Cooper, Jr., Long term effects of radiation and combined modalities on mouse lung. Scan. Electron Microsc. 22, 1-228 (1986).
4. M. Hareyama, M. Satoh, M. Yamagishi, M. Tamakawa, A. Oouchi, M. Shidou, H. Nagakura, S. Koiwai and K. Morita, Radiation tolerance of normal lung-pulmonary radiation syndrome. Jpn. J. Cancer Clinics 36, 2319-2325 (1990).
5. C. Belka, W. Budach, R. D. Kortmann and M. Bamberg, Radiation induced CNS toxicity-molecular and cellular mechanisms. Br. J. Cancer 85, 1233-1239 (2001).
6. P. Rubin, J. Finkelstein and D. Shapiro, Molecular biology mechanisms in the radiation induction of pulmonary injury syndromes: Interrelationship between the alveolar macrophage and the septal fibroblast. Int. J. Radiat. Oncol. Biol. Phys. 24, 93-101 (1992).
7. J. N. Finkelstein, C. J. Johnston, R. Baggs and P. Rubin, Early alterations in extracellular matrix and transforming growth factor beta gene expression in mouse lung indicative of late radiation fibrosis. Int. J. Radiat. Oncol. Biol. Phys. 28, 621-631 (1994).
8. C. J. Johnston, B. Piedboeuf, P. Rubin, J. P. Williams, R. Baggs and J. N. Finkelstein, Early and persistent alterations in the expression of interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor alpha mRNA levels in fibrosis-resistant and sensitive mice after thoracic irradiation. Radiat. Res. 145, 762-767 (1996).
9. J. H. Hong, C. S. Chiang, I. L. Campbell, J. R. Sun, H. R. Withers and W. H. McBride, Induction of acute phase gene expression by brain irradiation. Int. J. Radiat. Oncol. Biol. Phys. 33, 619-626 (1995).
10. J. H. Hong, C. S. Chiang, C. Y. Tsao, P. Y. Lin, W. H. McBride and C. J. Wu, Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation. Int. J. Radiat. Biol. 75, 1421-1427 (1999).
11. P. Rubin, C. J. Johnston, J. P. Williams, S. McDonald and J. N. Finkelstein, A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int. J. Radiat. Oncol. Biol. Phys. 33, 99-109 (1995).
12. M. Martin, J-L. LeFaix and S. Delanian, TGF-β1 and radiation fibrosis: A master switch and a specific therapeutic target? Int. J. Radiat. Oncol. Biol. Phys. 47, 277-290 (2000).
13. L. F. Fajardo, M. Berthrong and R. E. Anderson, Radiation Pathology. Oxford University Press, New York, 2001.
14. D. P. Penney and P. Rubin, Specific early fine structural changes in the lung irradiation. Int. J. Radiat. Oncol. Biol. Phys. 1, 1123-1132 (1977).
15. J. Sharplin and A. J. Franko, A quantitative histological study of strain-dependent differences in the effects of irradiation on mouse lung during the early phase. Radiat. Res. 119, 1-14 (1989).
16. J. Sharplin and A. J. Franko, A quantitative histological study of strain-dependent differences in the effects of irradiation on mouse lung during the intermediate and late phases. Radiat. Res. 119, 15-31 (1989).
17. D. P. Penney, D. W. Siemann, P. Rubin and K. Maltby, Morphological correlates of fractionated radiation of the mouse lung: Early and late effects. Int. J. Radiat. Oncol. Biol. Phys. 29, 789-804 (1994).
18. P. Rubin and G. W. Casarett, Clinical Radiation Pathology, Vols. I and II. W. B. Saunders, Philadelphia, 1968.
19. R. A. Rosiello and W. W. Merrill, Radiation-induced lung injury. Clin. Chest Med. 11, 65-71 (1990).
20. G. W. Morgan and S. N. Breit, Radiation and the lung: A reevaluation of the mechanisms mediating pulmonary injury. Int. J. Radiat. Oncol. Biol. Phys. 31, 361-369 (1995).
21. C. J. Johnston, T. W. Wright, P. Rubin and J. N. Finkelstein, Alterations in the expression of chemokine mRNA levels in fibrosis-resistant and sensitive mice after thoracic irradiation. Exp. Lung Res. 24, 321-337 (1998).
22. C. J. Johnston, J. P. Williams, P. Okunieff and J. N. Finkelstein, Radiation-induced pulmonary fibrosis: Examination of chemokine and chemokine receptor families. Radiat. Res. 157, 256-265 (2002).
23. A. M. Gotto, Jr., Treating hypercholesterolemia: looking forward. Clin. Cardiol. 26, 121-128 (2003).
24. D. E. Grobbee and M. L. Bots, Statin treatment and progression of atherosclerotic plaque burden. Drugs 63, 893-911 (2003).
25. L. Diomede, D. Albani, M. Sottocorno, M. B. Donati, M. Bianchi, P. Fruscella and M. Salmona, In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler. Thromb. Vasc. Biol. 21, 1327-1332 (2001).
26. A. W. Chan, D. L. Bhatt, D. P. Chew, J. Reginelli, J. P. Schneider, E. J. Topol and S. G. Ellis, Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 107, 1750-1756 (2003).
27. S. Morikawa, W. Takabe, C. Mataki, T. Kanke, T. Itoh, Y. Wada, A. Izumi, Y. Saito, T. Hamakubo and T. Kodama, The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J. Atheroscler. Thromb. 9, 178-183 (2002).
28. P. Chomczynski and N. Sacchi, Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156-159 (1987).
29. H. R. Withers and W. H. McBride, Biologic basis of radiation therapy. In Principles and Practice of Radiation Oncology (C. A. Perez and L. W. Brady, Eds.). Lippincott-Raven, Philadelphia, 1998.
30. A. C. Ruifrok and W. H. McBride, Growth factors: Biological and clinical aspects. Int. J. Radiat. Oncol. Biol. Phys. 43, 877-881 (1999).
31. J. Williams, Y. Chen, P. Rubin, J. Finkelstein and P. Okunieff, The biological basis of a comprehensive grading system for the adverse effects of cancer treatment. Semin. Radiat. Oncol. 13, 182-188 (2003).
32. D. L. Shapiro, J. N. Finkelstein, P. Rubin, D. P. Penney and D. W. Siemann, Radiation induced secretion of surfactant from cell cultures of type II pneumocytes: An in vitro model of radiation toxicity. Int. J. Radiat. Oncol. Biol. Phys. 10, 375-378 (1984).
33. J. N. Finkelstein, Physiologic and toxicologic responses of alveolar type II cells. Toxicology 60, 41-52 (1990).
34. P. Rubin, D. W. Siemann, D. L. Shapiro, J. N. Finkelstein and D. P. Penney, Surfactant release as an early measure of radiation pneumonitis. Int. J. Radiat. Oncol. Biol. Phys. 9, 1669-1673 (1983).
35. C. M. Roberts, E. Foulcher, J. J. Zaunders, D. H. Bryant, J. Freund, D. Cairns, R. Penny, G. W. Morgan and S. N. Breit, Radiation pneumonitis: A possible lymphocyte-mediated hypersensitivity reaction. Ann. Intern. Med. 118, 696-700 (1993).
36. E. L. Travis, J. D. Down, S. J. Holmes and B. Hobson, Radiation pneumonitis and fibrosis in mouse lung assayed by respiratory frequency and histology. Radiat. Res. 84, 133-143 (1980).
37. B. Schieffer and H. Drexler, Role of 3-hydroxy-3-methylglutaryl co-enzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases. Am. J. Cardiol. 91, 12H-18H (2003).
38. C. P. Sparrow, C. A. Burton, M. Hernandez, S. Mundt, H. Hassing, S. Patel, R. Rosa, A. Hermanowski-Vosatka, P. R. Wang and S. D. Wright, Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler. Thromb. Vasc. Biol. 21, 115-121 (2001).
39. A. M. Lefer, R. Scalia and D. J. Lefer, Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: New concepts for cardiovascular disease. Cardiovasc. Res. 49, 281-287 (2001).
40. A. Undas, J. Brozek and J. Musial, Anti-inflammatory and antithrombotic effects of statins in the management of coronary artery disease. Clin. Lab. 48, 287-296 (2002).
41. D. J. Lefer, Statins as potent antiinflammatory drugs. Circulation 106, 2041-2042 (2002).
42. A. C. Sposito and M. J. Chapman, Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler. Thromb. Vasc. Biol. 22, 1524-1534 (2002).
43. Y. S. Park, C. Guijarro, Y. Kim, Z. A. Massy, B. L. Kasiske, W. F. Keane and M. P. O'Donnell, Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am. J. Kidney Dis. 31, 190-194 (1998).
44. J. Martinez-Gonzalez, J. Alfon, M. Berrozpe and L. Badimon, HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. Atherosclerosis 159, 27-33 (2001).
45. A. Rezaie-Majd, T. Maca, R. A. Bucek, P. Valent, M. R. Muller, P. Husslein, A. Kashanipour, E. Minar and M. Baghestanian, Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 22, 1194-1199 (2002).
46. T. Waehre, J. K. Damas, L. Gullestad, A. M. Holm, T. R. Pedersen, K. E. Arnesen, H. Torsvik, S. S. Froland, A. G. Semb and P. Aukrust, Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J. Am. Coll. Cardiol. 41, 1460-1467 (2003).
47. B. Kwak, F. Mulhaupt, S. Myit and F. Mach, Statins as a newly recognized type of immunomodulator. Nat. Med. 6, 1399-1402 (2000).
48. U. Laufs, Beyond lipid-lowering: Effects of statins on endothelial nitric oxide. Eur. J. Clin. Pharmacol. 58, 719-731 (2003).
49. Y. Kureishi, Z. Luo, I. Shiojima, A. Bialik, D. Fulton, D. J. Lefer, W. C. Sessa and K. Walsh, The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6, 1004-1010 (2000).
50. D. Pruefer, J. Makowski, M. Schnell, U. Buerke, M. Dahm, H. Oelert, U. Sibelius, U. Grandel, F. Grimminger and M. Buerke, Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation 106, 2104-2110 (2002).
51. R. M. Strieter, Mechanisms of pulmonary fibrosis: Conference summary. Chest 120, 77S-85S (2001).
52. J. A. Belperio, M. P. Keane, M. D. Burdick, J. P. Lynch, 3rd., Y. Y. Xue, S. L. Kunkel and R. M. Strieter, Elevated levels of monocyte chemoattractant protein-1 are associated with bronchiolitis obliterans syndrome, a fibrotic disease of the small airway. Chest 120, 2S (2001).
53. B. B. Moore, R. Paine, 3rd., P. J. Christensen, T. A. Moore, S. Sitterding, R. Ngan, C. A. Wilke, W. A. Kuziel and G. B. Toews, Protection from pulmonary fibrosis in the absence of CCR2 signaling. J. Immunol. 167, 4368-4377 (2001).
54. D. Sheppard, Pulmonary fibrosis: A cellular overreaction or a failure of communication? J. Clin. Invest. 107, 1501-1502 (2001).
55. J. Gauldie, Pro: Inflammatory mechanisms are a minor component of the pathogenesis of idiopathic pulmonary fibrosis. Am. J. Crit. Care Med. 165, 1205-1208 (2002).
56. M. Selman, T. E. King and A. Pardo, Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 134, 136-151 (2001).